Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study.

@article{Phua2009SafetyAE,
  title={Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study.},
  author={Kong Boo Phua and Fong Seng Lim and Yu Lung Lau and E Anthony S Nelson and Li Min Huang and Seng Hock Quak and Bee Wah Lee and Yee Leong Teoh and Haiwen Tang and Irving Charles Boudville and Lidia Oostvogels and Pemmaraju Venkata Suryakiran and Igor V Smolenov and Htay Htay Han and Hans Ludwig Bock},
  journal={Vaccine},
  year={2009},
  volume={27 43},
  pages={5936-41}
}
This study evaluates the safety and efficacy against severe rotavirus gastroenteritis of the oral live attenuated human rotavirus vaccine RIX4414 (Rotarix) during the first 2 years of life in Asian infants from high-income countries. Healthy infants were enrolled to receive 2 doses of RIX4414 (N=5,359) or placebo (N=5,349). From 2 weeks post-dose 2 to 2 years of age, vaccine efficacy was 96.1% (95%CI:85.1%; 99.5%) against severe rotavirus gastroenteritis, 100% (95%CI:80.8%; 100%) against wild… CONTINUE READING